Tirzepatide and the shift to research-grade GLP-1s

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA as Mounjaro (for type-2 diabetes, 2022) and Zepbound (for weight management, 2023). The research-chemical supply has grown substantially as FDA compounding restrictions tightened.

Pharmacology in brief

The dual mechanism produces larger average weight loss than semaglutide in head-to-head Phase 3 trials (SURPASS, SURMOUNT). Typical dosing in clinical settings is titrated from 2.5 mg weekly.

Research-grade vs. compounded vs. branded

Research-grade tirzepatide is sold at a fraction of branded retail cost. The tradeoff is purity variance, lack of FDA oversight, and unknown batch-to-batch consistency. Pepticker's rubric quantifies that risk per vendor.